
|Articles|April 4, 2016
Disease Interception and the US National Cancer Moonshot
Author(s)DIA
Advertisement
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
2
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
3
Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
4
The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels
5




